Arbutus Q2 net income $2.5M; revenue $10.7M; Dr. Sawhney joins Board

Arbutus Biopharma Corp

Q2 net income of $2.5M ($0.01 per share) vs loss of $19.8M in Q2 2024; total revenue $10.7M, up from $1.7M.
Revenue increase primarily due to recognition of deferred revenue from termination of Qilu partnership; cash and equivalents $98.1M.
Dr. Roger Sawhney appointed to Board effective Aug 4, 2025, succeeding Anuj Hasija who resigned to join Vertex.
In Moderna U.S. litigation, summary judgment phase began July 2025; jury trial scheduled March 2026.
R&D expenses down to $5.5M from $15.6M due to restructuring; G&A down to $3.3M from $7.5M.

item 2.02item 5.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.